Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial

作者：Frederick Johan Raal, Jean Bergeron, Daniel Gaudet, Robert S. Rosenson, DAVID R. SULLIVAN, Traci A. Turner, Robert Alexander Hegele, Christie Mitchell Ballantyne, Joshua W. Knowles, Nicholas J. Leeper, Ira J. Goldberg, Rong Zhou, Ma'An Muhsin, Jennifer L. Hellawell, James Hamilton, Gerald F. Watts · 发表于：The Lancet Diabetes & Endocrinology · 年份：2025 · DOI：10.1016/s2213-8587(25)00290-6 · 被引用次数：22 · 研究领域：Lipid metabolism and disorders、Lipoproteins and Cardiovascular Health、Growth Hormone and Insulin-like Growth Factors